Edition:
India

Retrophin Inc (RTRX.OQ)

RTRX.OQ on NASDAQ Stock Exchange Global Market

21.26USD
2:29am IST
Change (% chg)

$-0.78 (-3.54%)
Prev Close
$22.04
Open
$22.13
Day's High
$22.13
Day's Low
$21.01
Volume
89,440
Avg. Vol
106,313
52-wk High
$26.43
52-wk Low
$15.57

Chart for

About

Retrophin, Inc. is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its... (more)

Overall

Beta: 1.38
Market Cap(Mil.): $948.89
Shares Outstanding(Mil.): 38.39
Dividend: --
Yield (%): --

Financials

BRIEF-Retrophin reports third quarter 2017 financial results

* Q3 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S

08 Nov 2017

Martin Shkreli seeks to overturn part of his conviction

NEW YORK Former drug company executive Martin Shkreli on Friday asked a judge to throw out part of his criminal conviction, a day after prosecutors sought to have him jailed until his sentencing.

09 Sep 2017

UPDATE 1-Martin Shkreli seeks to overturn part of his conviction

NEW YORK, Sept 8 Former drug company executive Martin Shkreli on Friday asked a judge to throw out part of his criminal conviction, a day after prosecutors sought to have him jailed until his sentencing.

09 Sep 2017

BRIEF-Retrophin reports Q2 loss per share $0.34

* Q2 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S

10 Aug 2017

Jury in Martin Shkreli trial seeks clarity on 'fraudulent intent'

NEW YORK, Aug 1 Jurors in the trial of former drug company executive Martin Shkreli on Tuesday asked a judge to clarify the definition of "fraudulent intent," a key element of the case, in their first significant note since they began deliberating Monday morning.

02 Aug 2017

BRIEF-Retrophin commences patient dosing in international, registrational phase 3 trial of RE-024 in PKAN

* Retrophin commences patient dosing in international, registrational phase 3 trial of re-024 in pkan

25 Jul 2017

CEO of Martin Shkreli's old company likens him to 'Pied Piper'

The CEO of Retrophin Inc, the drug company that Martin Shkreli founded and is now accused of conspiring to defraud, compared Shkreli to the Pied Piper on Thursday as he tried to explain to jurors why he stuck with the company in its early days despite misgivings.

14 Jul 2017

CEO of Martin Shkreli's old company likens him to 'Pied Piper'

The CEO of Retrophin Inc , the drug company that Martin Shkreli founded and is now accused of conspiring to defraud, compared Shkreli to the Pied Piper on Thursday as he tried to explain to jurors why he stuck with the company in its early days despite misgivings.

14 Jul 2017

CEO of Martin Shkreli's old company likens him to 'Pied Piper'

July 13 The CEO of Retrophin Inc, the drug company that Martin Shkreli founded and is now accused of conspiring to defraud, compared Shkreli to the Pied Piper on Thursday as he tried to explain to jurors why he stuck with the company in its early days despite misgivings.

14 Jul 2017

Former Retrophin chairman says Martin Shkreli lied 'to my face'

Martin Shkreli was ousted as chief executive of drug company Retrophin Inc after disobeying directions from the board of directors and lying about it, the board's former chairman testified at Shkreli's securities fraud trial on Wednesday.

13 Jul 2017

Earnings vs. Estimates